Efficacy and safety of oxaliplatin-based chemotherapy in elderly patients with advanced colorectal cancer - 06/04/13
Abstract |
Purpose |
The incidence of colorectal cancer in elderly patients has increased markedly in China. This study was aimed to analyze the efficacy and tolerance of oxaliplatin-based chemotherapy in elderly patients with advanced colorectal cancer.
Methods |
We carried out a retrospective analysis using date of 41 advanced colorectal cancer patients who received oxaliplatin-based chemotherapy with an age of 65 years or above.
Results |
Among 41 enrolled patients, 24 received XELOX and 17 received FOLFOX. The overall response rate was 36.6%, the disease control rate was 73.2%, including 15 partial response, 15 stable disease and 11 progressive disease. The median progression-free survival and median overall survival was 7.5 months (95%CI: 6.54 8.46 months) and 23.0 months (95%CI: 15.35 30.64 months) respectively. Patients with lower CEA level (CEA≤5ng/ml) before treatment get a longer median progression-free survival than other patients (7.5 months vs 7.0 months; P=0.026), but the overall survival differences did not reach statistical significance. The toxicity was tolerable, the main 3 or 4 grade hematological and non-hematological toxicities were neutropenia (n=6,14.6%) and diarrhea (n=2,4.8%). No treatment-related death was found.
Conclusions |
The oxaliplatin-based chemotherapy was efficacy and safety in elderly patients with advanced colorectal cancer, and should be considered as an effective treatment for Chinese elderly patients.
Le texte complet de cet article est disponible en PDF.Keywords : Advanced colorectal cancer, Oxaliplatin, Elderly patients
Plan
A project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), project number: JX10231801. |
Vol 3 - N° 1
P. 1-6 - janvier 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?